Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. - Wikidata - awgldk - TriplyDB

Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma.

Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma.

http://www.wikidata.org/entity/Q40700869

about

Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?Clinical application of 18F-fluorodeoxyglucose positron emission tomography for assessment and evaluation after therapy for malignant hepatic tumor [18F]fludeoxyglucose positron emission tomography and computed tomography as a prognostic tool before liver transplantation, resection, and loco-ablative therapies for hepatocellular carcinoma.Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE).Does 18F-FDG positron emission tomography-computed tomography have a role in initial staging of hepatocellular carcinoma?18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies.Positron emission tomography/computer tomography: challenge to conventional imaging modalities in evaluating primary and metastatic liver malignancies Surgical management of hepatic malignancy.Prognostic significance of parameters from pretreatment (18)F-FDG PET in hepatocellular carcinoma: a meta-analysis.Diagnostic value for extrahepatic metastases of hepatocellular carcinoma in positron emission tomography/computed tomography scan.Prognostic value of pretreatment (18)F-FDG PET-CT in radiotherapy for patients with hepatocellular carcinoma.Metabolic Activity by 18F-FDG-PET/CT Is Prognostic for Stage I and II Pancreatic Cancer Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we?Predictive and prognostic value of FDG-PET.Comparison of the effectiveness of MRI perfusion and fluorine-18 FDG PET-CT for differentiating radiation injury from viable brain tumor: a preliminary retrospective analysis with pathologic correlation in all patients Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies.Clinical applications of (18)F-FDG PET in the management of hepatobiliary and pancreatic tumors.Hepatic radioembolization as a bridge to liver surgery.Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas.Diagnostic role of radiolabelled choline PET or PET/CT in hepatocellular carcinoma: a systematic review and meta-analysis.Significance of preoperative fluorodeoxyglucose-positron emission tomography in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients: a Japanese multicenter study.The role of preoperative [18F]fluorodeoxyglucose positron emission tomography in predicting early recurrence after curative resection of hepatocellular carcinomas.Clinical applications of positron emission tomography in hepatic tumors.18F-FDG-PET for Assessing Biological Viability and Prognosis in Liver Transplant Patients with Hepatocellular Carcinoma Positron emission tomography for staging and assessment of tumor response of hepatic malignancies.Frequent alteration of the protein synthesis of enzymes for glucose metabolism in hepatocellular carcinomas.Is quantitation necessary for oncological PET studies? Against.(18)F-FDG-PET/CT predicts early tumor recurrence in living donor liver transplantation for hepatocellular carcinoma.Feasibility of optimizing the dose distribution in lung tumors using fluorine-18-fluorodeoxyglucose positron emission tomography and single photon emission computed tomography guided dose prescriptions.Imaging Cancer Metabolism.Assessment of [(18)F]-fluoroacetate PET/CT as a tumor-imaging modality: preclinical study in healthy volunteers and clinical evaluation in patients with liver tumor.Prognostic implication of (18)F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study.Quantitative analysis of tumor growth rate and changes in tumor marker level: specific growth rate versus doubling time.[Combined PET-MRI of the abdomen].The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis.Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.Prognosis of preoperative positron emission tomography uptake in hepatectomy patients.11C-acetate and 18F-fluorodeoxyglucose positron emission tomography/computed tomography dual imaging for the prediction of response and prognosis after transarterial chemoembolization

P2860

Q26784218-9B569049-74DC-4F0E-9AA2-6EF817E11278 Q27005824-91C05CB2-5AD7-43E3-A2FA-685FEEC6FBD1 Q27691331-F6A59241-EACF-42A0-B0A0-DBA337048B43 Q30479629-F1AF18E9-A9F8-4D76-AD1B-C2EEB0D17E5C Q33686817-9A283F86-8282-45FC-860F-25B2702ACABC Q34083775-03DF426B-D4A2-4744-B5D5-58955AC47388 Q35127213-154044B7-3EE4-42CD-9595-BC78E8BD3D19 Q35397108-9BF5B2BD-F169-4B48-B0F4-75C3182A169B Q35806757-4F31EC07-269E-4F63-BBBC-0358499D5A1B Q35910220-F55C4817-5EF9-4E94-89C4-FB6711C81B5C Q36049920-8AB7CA33-7986-4945-B698-3F7AB781CD31 Q36166863-5A36DA3A-BEFD-45C3-B14A-0BE0AF27FFC2 Q36540475-4849621C-45E5-4A85-B19F-9D0A24A6C169 Q37088265-BABBF3E7-DA09-4AF9-9D5F-1C3FDC886F26 Q37129057-E194AB3F-EA4B-40D6-923A-62F5EBC222AA Q37212449-EA3E5F95-65F9-4FFC-BDF3-8E80F6E8EE2F Q37263149-43EA845B-B604-46E4-98D1-E7B71FA3EBCA Q38004855-19B92440-63E1-497D-A148-9880DDE01650 Q38240151-22C7F414-C8DA-408E-A031-8FCA695C48CA Q38504053-00F60B07-A42F-4B41-92B7-FB8F1C1735A0 Q38552509-54AE8477-EBF6-4251-B267-031D1BCDBE3E Q39223475-2D2FE882-8F3D-4954-8369-9056E299478F Q39709255-2C7B130E-C4E6-4574-A788-E56DB6D9720C Q39734745-3DCBA2BA-5134-462D-A114-3DBF078AC526 Q41706815-1C85D21C-2EAB-4B3D-8272-38B3E59454DB Q41951499-7320CE3F-EAF3-41C3-A465-6F4F29C43D0D Q42867141-5A0AB08D-034D-428D-84C8-C5E209A7A334 Q43876090-C6AF8F99-8597-402A-8E8A-7A8FD3DB7CC1 Q43899644-9B379846-50CE-4EA5-8A40-7D75D07C0FA7 Q44983243-B31860FF-1ED9-4B41-9FF1-47B61AE9FDFC Q47117264-5C55B509-6C8D-482B-80B1-89813D0DE327 Q51155857-52C5BEEF-382C-4080-B10C-505262B6B2D8 Q51750656-127C0FB1-C4FB-4AA7-95B9-8866624B9C21 Q51847247-82F149C5-EE76-4D10-9D8F-E9CB125B9B19 Q52987725-B0F01628-B035-487B-B7E7-8E466F8C40EA Q53027673-72BF4A14-768E-4F68-A81F-D62974FD794F Q53214416-14A0A803-289E-409A-A81A-E792CCBDB6EA Q54239712-164E8536-2E42-4615-8A73-5F0C75366FDC Q58739392-A76E3A30-4B96-4455-A3B7-11F5166EE120

P2860

Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma.

http://www.wikidata.org/entity/Q40700869

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

2001年论文

@zh

2001年论文

@zh-cn

name

Usefulness of positron emissio ...... with hepatocellular carcinoma.

@en

type

label

Usefulness of positron emissio ...... with hepatocellular carcinoma.

@en

prefLabel

Usefulness of positron emissio ...... with hepatocellular carcinoma.

@en

P1433

Q40700869-BC905DF8-FD25-4D03-8890-E108F623EEF0

P1476

Q40700869-76580B19-41DC-40E6-BA1F-9F1A96924738

P2093

Q40700869-0FD331CD-039C-468B-B782-D41FEE62457D

Q40700869-13875A7A-E2C7-4046-B4BD-FA8182DF2081

Q40700869-2EEAE020-DE3A-49DE-8868-AC470F79BB80

Q40700869-43DC5E7F-2B70-453E-9472-86B124C9D6CF

Q40700869-4CC4F9D7-7BC6-48D7-AB14-DDF309643553

Q40700869-7D781B33-4961-4C9A-9506-16BD1B00DC41

Q40700869-8153DC9C-DE42-42E8-93AA-CB0A7B38B493

Q40700869-A2A939D5-F575-4610-B7AC-C01616923C57

Q40700869-C05835EF-4128-498B-A36F-B5AC93F8F340

Q40700869-D4444DBE-1E2A-46CD-8C36-5385D943D370

P304

Q40700869-920CC975-9423-4B43-92CE-19DDDCE9DD3C

P31

Q40700869-59AC360A-AD54-40FF-A470-8E19B1E02955

P356

Q40700869-5F20D145-58A8-45EC-92ED-A4AD3D2D5CFB

P407

Q40700869-FFCE19CB-1308-4DF0-BAF0-3921ABF3A23F

P433

Q40700869-1865E6E1-BF66-48B1-964A-FB3ECAE24795

P478

Q40700869-97B0A936-0632-4478-9DD3-35DD964198C2

P577

Q40700869-6D973ED2-DA47-4E30-8A3C-EC5A07F151A5

P5875

Q40700869-971BC3AA-2704-476F-A89A-E7BED63A0093

P698

Q40700869-F18D5083-D859-4B74-ADC2-77D3C160DBEC

P356

J.1572-0241.2001.03888.X

P1433

The American Journal of Gastroenterology

P1476

Usefulness of positron emissio ...... with hepatocellular carcinoma.

@en

P2093

Habu D

http://www.w3.org/2001/XMLSchema#string

Ishizu H

http://www.w3.org/2001/XMLSchema#string

Iwata Y

http://www.w3.org/2001/XMLSchema#string

Kubo S

http://www.w3.org/2001/XMLSchema#string

Nishiguchi S

http://www.w3.org/2001/XMLSchema#string

Ochi H

http://www.w3.org/2001/XMLSchema#string

Sasaki N

http://www.w3.org/2001/XMLSchema#string

Shiomi S

http://www.w3.org/2001/XMLSchema#string

Takeda T

http://www.w3.org/2001/XMLSchema#string

Tamori A

http://www.w3.org/2001/XMLSchema#string

P304

1877-1880

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1572-0241.2001.03888.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P577

2001-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11920277

http://www.w3.org/2001/XMLSchema#string

P698

11419843

http://www.w3.org/2001/XMLSchema#string